NasdaqGM:ORKABiotechs
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin
Oruka Therapeutics (ORKA) shares have been moving after the company added Chris Martin to its board, a commercial veteran whose launch and M&A track record could reshape how investors think about Oruka’s pipeline.
See our latest analysis for Oruka Therapeutics.
The market seems to be buying into that narrative already, with a 1 day share price return of 13.11% and a 90 day share price return of 104.63%. The 1 year total shareholder return of 51.62% suggests momentum has been building rather...